明陽智能(601615.SH):股東簽署表決權委託協議
格隆匯12月1日丨明陽智能(601615.SH)公佈,股東北海瑞悦創業投資有限公司(簡稱“北海瑞悦”)將其所持有的明陽智能2,262,876股,佔公司總股本(即2,271,759,206股)0.10%的股份代表的全部表決權委託給明陽智能控股股東明陽新能源投資控股集團有限公司(簡稱“能投集團”)行使。本次表決權委託完成後,能投集團將控制公司25.44%股份所代表的表決權。
本次權益變動後,能投集團仍為公司唯一控股股東,公司實際控制人合計持有公司股份的數量和比例均未發生變化,因此,公司實際控制人不發生變化。本次權益變動不會影響公司的治理結構和持續經營。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.